[Contemporary treatment of gastrointestinal stromal tumors].
Great revolutionary changes have occurred in the diagnosis and treatment of gastrointestinal stromal tumor(GIST) due to the discovery and development of molecularly targeted therapy with imatinib and sunitinib, which have led to publication of several clinical guidelines for GIST. However, despite enhanced understanding of the clinical and molecular nature of GIST, there are many problems still remain. In this paper, I will focus on three GIST issues of great interest including: 1) laparoscopic surgery for GIST and gastrointestinal submucosal tumors; 2)multidisciplinary treatments for GIST, such as adjuvant therapy, neoadjuvant therapy, surgery during imatinib treatment, and surgery for focally imatinib-resistant GIST; and 3)the diagnosis and treatment of imatinib-resistant GIST.
Nishida
Toshirou
T
Department of Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D046152:Gastrointestinal Stromal Tumors / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D010535:Laparoscopy
D000970:Antineoplastic Agents